You know all about the effects and efficacy of Trametinib tablets, so don’t be confused about scientific medication use!

Trametinib is a highly selective MEK inhibitor, mainly used to treat malignant melanoma, thyroid cancer, and metastatic non-small cell lung cancer with BRAF V600 mutations. It inhibits the activity of MEK1 and MEK2 protein kinases and blocks the MAPK signaling pathway, thereby inhibiting the proliferation and growth of tumor cells.

In clinical practice, trametinib is often used in combination with dabrafenib (Dabrafenib). Studies have shown that this combination treatment regimen significantly improves progression-free survival (PFS) and overall survival (OS), and can reduce drug resistance problems better than using BRAF inhibitors alone. For example, in patients with advanced melanoma with BRAF V600 mutations, the objective response rate (ORR) of trametinib combined with dabrafenib exceeded 60%, greatly extending the patient's survival time.

For BRAF mutated non-small cell lung cancer, trametinib combined with dabrafenib has also shown good efficacy, and the FDA has approved this combination for first-line or second-line treatment. In patients with anaplastic thyroid cancer (ATC), this combination regimen has also been proven to significantly delay the progression of the disease, making it an important option for the treatment of this rare cancer.

The recommended dose of trametinib is usually2 mg, once a day, and should be taken on an empty stomach to ensure optimal absorption. Common adverse reactions include rash, diarrhea, hypertension, abnormal liver function, etc. Therefore, liver and kidney function and cardiovascular status need to be monitored regularly during medication. In addition, because MEK inhibitors may affect retinal health, patients on long-term medication should undergo regular eye examinations.

Scientific and reasonable medication can help patients better control their condition and improve their quality of life. For patients who meet the indications, trametinib is an important choice in targeted therapy, but it still needs to be used under the guidance of a doctor to ensure safety and effectiveness.

Reference materials:https://go.drugbank.com/drugs/DB08911